Advertisement

Neurobiologie dementieller Syndrome — Neurochemie und Neuropharmakologie der Nootropika

  • H. Coper
Conference paper

Zusammenfassung

„Die Behandlung des Altersblödsinns hat naturgemäß meist nur einen sehr engen Spielraum. So ziemlich alles, was geschehen kann, ist sorgsame körperliche Pflege und Überwachung der oft gebrechlichen und hinfälligen Kranken, Regelung der gesamten Lebensweise, besonders der Ernährung und der Verdauung, Bekämpfung der Angst durch kleine Opiumgaben, der Schaflosigkeit durch Bäder, vorsichtige Wicklungen, gelegentliche Darreichungen von Paraldehyd oder Veronal. In den delirösen Aufregungszuständen ist häufiger die Anwendung des Polsterbettes oder des Dauerbades sowie die Sondenernährung mit oder ohne Zusatz eines Beruhigungsmittels notwendig. Andererseits ist bei den ruhigen Schwachsinnsformen die Anstaltsbehandlung vielfach unnötig und durch die Verpflegung in der Familie oder in einer Pfründe vollständig zu ersetzen.“

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baltes PB, Willis SL (1982) Plasticity and enhancement of intellectual functioning in old age: Penn State’s adult development and enrichment program (ADEPT). In: Craik FI, Trehub S (eds) Aging and cognitive processes. Plenum Press, New York, pp 353–389Google Scholar
  2. Bartus RT, Dean RL, Beer B (1984) Cholinergic precursor therapy for geriatric cognition. Its past, its present and a question of its future. In: Ordy JM, Harman D, Alfin-Slater RB (eds) Nutrition in gerontology. Raven Press, New York, pp 191–225Google Scholar
  3. Bartus RT, Dean RL, Pontocorvo M, Flicker C (1985) The cholinergic hypothesis a historical, current perspective and future direction. Ann NY Acad Sci 332–358Google Scholar
  4. Bartus RT, Dean RL, Fisher SKL (1986). Cholinergic treatment for age related memory disturbances: Dead or barely coming of age. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 421–450Google Scholar
  5. Bente D (1982) Vigilanzregulation, hirnorganisches Psychosyndrom and Alterserkrankungen: Ein psychophysiologisches Modell. In: Bente D, Coper H, Kanowski S (eds) Hirnorganisches Psychosyndrom im Alter — Konzepte and Modelle für die pharmakologische Forschung. Springer, Berlin Heidelberg New York, S 63–73Google Scholar
  6. Bonhoff G, Lewerenz H (1954) Über Weckamine (Pervitin and Benzedrin). Springer, Berlin Göttingen HeidelbergGoogle Scholar
  7. Bowen D, Smith C, White P, Davison M (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophics. Brain 99: 459–496PubMedCrossRefGoogle Scholar
  8. Branconnier RJ, Cole JO (1981) Effects of acute administration of trazodon and amitriptylin on cognition, cardiovascular function, and salivation in the normal geriatric subject. J Clin Psychopharmacol 1: 82S–88SCrossRefGoogle Scholar
  9. Cavagnaro J (1986) Possible immunological treatments for Alzheimer’s disease. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 267–291Google Scholar
  10. CDGA, The Committee for „Geriatric Diseases and Asthenias“ at BGA (1986) Impaired brain functions in old age. AMI-Hefte 1/1986, Bundesgesundheitsamt, BerlinGoogle Scholar
  11. Crews FT, Meyer EM, Gonzales RA etal. (1986) Presynaptic and postsynaptic approaches to enhancing central cholinergic neurotransmission. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 385–419Google Scholar
  12. Coper H, Hellmann WM (1988) Psychostimulants, analeptics, nootropics: An attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217Google Scholar
  13. Coper H, Jänicke B, Schulze G (1986) Biophsychological research on the adaptivity across the life span of animals. In: Baltes PB, Featherman DL, Lerner RM (eds) Life-span development and behavior, Vol VII. Lawrence Erlebaum, London, pp 207–232Google Scholar
  14. Crews FT, Meyer EM, Gonzales RA etal. (1986) Presynaptic and postsynaptic approaches to enhancing central cholinergic neurotransmission. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 385–419Google Scholar
  15. De Smet Y, Ruberg M, Serdan M, Dubios B, L’Hermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161PubMedCrossRefGoogle Scholar
  16. Drachman DA (1977) Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 27: 783–790PubMedGoogle Scholar
  17. Drachman DA, Leavitt J (1974) Human memory and cholinergic system. A relationship to aging? Arch Neurol 30: 113–121PubMedGoogle Scholar
  18. Ghoneim MM, Mewaldt SP (1975) Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologia 44: 257–262PubMedCrossRefGoogle Scholar
  19. Giurgea CE (1972) Vers une pharmacologie de l’activité intégrative du cerveau. Tentative du concept nootrope en psychopharmacologie. Actual Pharmacol 25: 115–157Google Scholar
  20. Hock FJ (1987) Drug influences on learning and memory in aged animals and humans. Neuropsychobiology 17: 145–160PubMedCrossRefGoogle Scholar
  21. Hollister LE (1986a) Drug therapy of Alzheimer’s disease: Realistic or not? Prog Neuropsychopharmacol Biol Psychiatry 19: 439–446CrossRefGoogle Scholar
  22. Hollister LE (1986b) Summary and conclusions. In: Cook T, Bartus RT, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 617–677Google Scholar
  23. Jacobson A (1958) The use of ritalin in psychotherapy of depression of the aged. Psychiatr Q 32: 475–483Google Scholar
  24. Kastenbaum R, Slater PE, Aisenberg R (1954) Toward a conceptual model of geriatric psychopharmacology: An experiment with thioridazine an dextroamphetamine. Gerontologist 4: 68–71Google Scholar
  25. Kraepelin E (1910) Das senile and präsenile Irresein. In: Psychiatrie — Ein Lehrbuch für Studierende and Ärzte. Barth, LeipzigGoogle Scholar
  26. Lassen NA (1959) Cerebral blood flow and oxygen consumption in man. Physiol Rev 39: 183–238PubMedGoogle Scholar
  27. Loew DM Singer JM (1983) Stimulants and senility. In: Creese I (ed) Neurochemical behavioral and clinical perspectives. Raven Press, New York, pp 237–268Google Scholar
  28. Perlick D, Stastny P, Katz I, Mayer M, Mattis S (1986) Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 143: 230–232PubMedGoogle Scholar
  29. Post F (1972) Spezielle Alterspsychiatrie. In: Kisker KP, Meyer J-E, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart. Springer, Berlin Heidelberg New York, S 1077–1101Google Scholar
  30. Pouplart-Bathelaix A, Dubas F, Jabbour W, Maher I, Emile J (1986) An immunological view on the etiology and pathogenesis of Alzheimer’s disease. In: Bès A et al. (eds) Senile dementias: Early detection. John Libbey Eurotext, London, pp 216–222Google Scholar
  31. Rubner M (1908) Das Problem der Lebensdauer and seine Beziehung zu Wachstum and Ernährung. R. Oldenburg, MünchenGoogle Scholar
  32. Sadeh M, Braham J, Modau M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667PubMedGoogle Scholar
  33. Tomlinson BE, Blessed G, Roth M (1970) Observation on the brains of demented old people. J Neurol Sci 11: 205–242PubMedCrossRefGoogle Scholar
  34. Yesavage JA, Tinkelenberg JR, Berger PA, Hollister LE (1979) Vasodilators in senile dementia: A review of the literature. Arch Gen Psychiatry 36: 220–223Google Scholar
  35. Zornetzer SF (1986) The noradrenergic locus coeruleus and senescent memory dysfunction. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Madison/CT, pp 337–359Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. Coper
    • 1
  1. 1.Universitätsklinikum Charlottenburg, Psychiatrische Klinik (WE 12)Berlin 19Deutschland

Personalised recommendations